Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $53.58 million. The enterprise value is $39.10 million.
Important Dates
The last earnings date was Tuesday, March 10, 2026, before market open.
| Earnings Date | Mar 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 7.30 million shares outstanding. The number of shares has increased by 0.48% in one year.
| Current Share Class | 7.30M |
| Shares Outstanding | 7.30M |
| Shares Change (YoY) | +0.48% |
| Shares Change (QoQ) | +4.95% |
| Owned by Insiders (%) | 2.16% |
| Owned by Institutions (%) | 15.11% |
| Float | 6.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 27.11 |
| Forward PS | 131.32 |
| PB Ratio | 3.12 |
| P/TBV Ratio | 3.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 19.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.68, with a Debt / Equity ratio of 0.03.
| Current Ratio | 6.68 |
| Quick Ratio | 6.36 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.28% and return on invested capital (ROIC) is -36.09%.
| Return on Equity (ROE) | -54.28% |
| Return on Assets (ROA) | -32.81% |
| Return on Invested Capital (ROIC) | -36.09% |
| Return on Capital Employed (ROCE) | -71.64% |
| Weighted Average Cost of Capital (WACC) | 9.75% |
| Revenue Per Employee | $123,542 |
| Profits Per Employee | -$601,719 |
| Employee Count | 16 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Lipocine has paid $200 in taxes.
| Income Tax | 200 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +128.66% in the last 52 weeks. The beta is 1.02, so Lipocine's price volatility has been similar to the market average.
| Beta (5Y) | 1.02 |
| 52-Week Price Change | +128.66% |
| 50-Day Moving Average | 9.01 |
| 200-Day Moving Average | 4.63 |
| Relative Strength Index (RSI) | 38.02 |
| Average Volume (20 Days) | 133,301 |
Short Selling Information
The latest short interest is 141,136, so 1.93% of the outstanding shares have been sold short.
| Short Interest | 141,136 |
| Short Previous Month | 126,854 |
| Short % of Shares Out | 1.93% |
| Short % of Float | 2.13% |
| Short Ratio (days to cover) | 1.34 |
Income Statement
In the last 12 months, Lipocine had revenue of $1.98 million and -$9.63 million in losses. Loss per share was -$1.77.
| Revenue | 1.98M |
| Gross Profit | 1.98M |
| Operating Income | -10.37M |
| Pretax Income | -9.63M |
| Net Income | -9.63M |
| EBITDA | -10.31M |
| EBIT | -10.37M |
| Loss Per Share | -$1.77 |
Full Income StatementBalance Sheet
The company has $14.93 million in cash and $449,591 in debt, with a net cash position of $14.48 million or $1.98 per share.
| Cash & Cash Equivalents | 14.93M |
| Total Debt | 449,591 |
| Net Cash | 14.48M |
| Net Cash Per Share | $1.98 |
| Equity (Book Value) | 14.48M |
| Book Value Per Share | 2.35 |
| Working Capital | 14.35M |
Full Balance SheetCash Flow
| Operating Cash Flow | -9.76M |
| Capital Expenditures | n/a |
| Free Cash Flow | -9.76M |
| FCF Per Share | -$1.34 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -524.69% |
| Pretax Margin | -487.04% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Lipocine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.48% |
| Shareholder Yield | -0.48% |
| Earnings Yield | -17.97% |
| FCF Yield | -18.22% |
Analyst Forecast
The average price target for Lipocine is $15.00, which is 104.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.00 |
| Price Target Difference | 104.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 111.96% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 12, 2023. It was a reverse split with a ratio of 1:17.
| Last Split Date | May 12, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:17 |
Scores
Lipocine has an Altman Z-Score of -13.8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.8 |
| Piotroski F-Score | n/a |
